» Articles » PMID: 27570766

Putative Role of Red Wine Polyphenols Against Brain Pathology in Alzheimer's and Parkinson's Disease

Overview
Journal Front Nutr
Date 2016 Aug 30
PMID 27570766
Citations 60
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) and Parkinson's disease (PD) are the most common age-related neurodegenerative disorders and hence pose remarkable socio-economical burdens to both families and state. Although AD and PD have different clinical and neuropathological features, they share common molecular mechanisms that appear to be triggered by multi-factorial events, such as protein aggregation, mitochondrial dysfunction, oxidative stress (OS), and neuroinflammation, ultimately leading to neuronal cell death. Currently, there are no established and validated disease-modifying strategies for either AD or PD. Among the various lifestyle factors that may prevent or slow age-related neurodegenerative diseases, epidemiological studies on moderate consumption of red wine, especially as part of a holistic Mediterranean diet, have attracted increasing interest. Red wine is particularly rich in specific polyphenolic compounds that appear to affect the biological processes of AD and PD, such as quercetin, myricetin, catechins, tannins, anthocyanidins, resveratrol, and ferulic acid. Indeed, there is now a consistent body of in vitro and in vivo data on the neuroprotective effects of red wine polyphenols (RWP) showing that they do not merely possess antioxidant properties, but may additionally act upon, in a multi-target manner, the underlying key mechanisms featuring in both AD and PD. Furthermore, it is important that bioavailability issues are addressed in order for neuroprotection to be relevant in a clinical study scenario. This review summarizes the current knowledge about the major classes of RWP and places into perspective their potential to be considered as nutraceuticals to target neuropathology in AD and PD.

Citing Articles

A Comprehensive Review of Bioactive Tannins in Foods and Beverages: Functional Properties, Health Benefits, and Sensory Qualities.

Cosme F, Aires A, Pinto T, Oliveira I, Vilela A, Goncalves B Molecules. 2025; 30(4).

PMID: 40005115 PMC: 11858154. DOI: 10.3390/molecules30040800.


Molecular Signaling Pathways of Quercetin in Alzheimer's Disease: A Promising Arena.

Alsaleem M, Al-Kuraishy H, Al-Gareeb A, Albuhadily A, Alrouji M, Yassen A Cell Mol Neurobiol. 2024; 45(1):8.

PMID: 39719518 PMC: 11668837. DOI: 10.1007/s10571-024-01526-w.


Wine Phenolic Compounds: Chemistry, Functionality and Health Benefits.

El Rayess Y, Nehme N, Azzi-Achkouty S, Julien S Antioxidants (Basel). 2024; 13(11).

PMID: 39594454 PMC: 11591289. DOI: 10.3390/antiox13111312.


Modulation of Biological Membranes Using Small-Molecule Compounds to Counter Toxicity Caused by Amyloidogenic Proteins.

Seychell R, El Saghir A, Vassallo N Membranes (Basel). 2024; 14(11).

PMID: 39590617 PMC: 11596372. DOI: 10.3390/membranes14110231.


The Potential Effects of Red Wine and Its Components on Neurocognitive Disorders: A Narrative Review.

Boccardi V, Tagliafico L, Persia A, Page E, Ottaviani S, Cremonini A Nutrients. 2024; 16(20).

PMID: 39458427 PMC: 11510231. DOI: 10.3390/nu16203431.


References
1.
Hernan M, Chen H, Schwarzschild M, Ascherio A . Alcohol consumption and the incidence of Parkinson's disease. Ann Neurol. 2003; 54(2):170-5. DOI: 10.1002/ana.10611. View

2.
Trombino S, Cassano R, Ferrarelli T, Barone E, Picci N, Mancuso C . Trans-ferulic acid-based solid lipid nanoparticles and their antioxidant effect in rat brain microsomes. Colloids Surf B Biointerfaces. 2013; 109:273-9. DOI: 10.1016/j.colsurfb.2013.04.005. View

3.
Iriti M, Varoni E . Melatonin in Mediterranean diet, a new perspective. J Sci Food Agric. 2014; 95(12):2355-9. DOI: 10.1002/jsfa.7051. View

4.
Richard T, Poupard P, Nassra M, Papastamoulis Y, Iglesias M, Krisa S . Protective effect of ε-viniferin on β-amyloid peptide aggregation investigated by electrospray ionization mass spectrometry. Bioorg Med Chem. 2011; 19(10):3152-5. DOI: 10.1016/j.bmc.2011.04.001. View

5.
Lindsley C . Alzheimer's disease: development of disease-modifying treatments is the challenge for our generation. ACS Chem Neurosci. 2012; 3(11):804-5. PMC: 3503338. DOI: 10.1021/cn300190f. View